Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation
Antibody-mediated rejection (AMR) is caused by antibodies that recognize donor human leukocyte antigen (HLA) or other targets. As knowledge of AMR pathophysiology has increased, a combination of factors is necessary to confirm the diagnosis and phenotype. However, frequent modifications to the AMR d...
প্রধান লেখক: | Roufosse, C, Becker, JU, Rabant, M, Seron, D, Bellini, MI, Böhmig, GA, Budde, K, Diekmann, F, Glotz, D, Hilbrands, L, Loupy, A, Oberbauer, R, Pengel, L, Schneeberger, S, Naesens, M |
---|---|
বিন্যাস: | Journal article |
ভাষা: | English |
প্রকাশিত: |
Frontiers Media
2022
|
অনুরূপ উপাদানগুলি
-
Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation
অনুযায়ী: Seron, D, অন্যান্য
প্রকাশিত: (2022) -
Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
অনুযায়ী: Naesens, M, অন্যান্য
প্রকাশিত: (2022) -
Alloimmune risk stratification for kidney transplant rejection
অনুযায়ী: Bestard, O, অন্যান্য
প্রকাশিত: (2022) -
Allograft function as endpoint for clinical trials in kidney transplantation
অনুযায়ী: Hilbrands, L, অন্যান্য
প্রকাশিত: (2022) -
Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
অনুযায়ী: Tong, A, অন্যান্য
প্রকাশিত: (2022)